Progress in the pleiotropic activity of metformin
10.16438/j.0513-4870.2021-0464
- VernacularTitle:二甲双胍的多效性研究进展
- Author:
Wen-xuan XIAO
1
;
Ya-dan LUO
1
;
Jian-guo CHEN
2
;
Fang WANG
2
Author Information
1. Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
2. Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Hubei Key Laboratory of Drug Targeting and Pharmacokinetic Evaluation, Wuhan 430030, China
- Publication Type:Research Article
- Keywords:
metformin;
mental disorder;
cardiovascular system;
intestinal microbiota;
neoplasm
- From:
Acta Pharmaceutica Sinica
2021;56(12):3385-3391
- CountryChina
- Language:Chinese
-
Abstract:
Metformin, as a first-line drug in the treatment of type 2 diabetes, is widely used in clinic with definite efficacy and few adverse reactions. In recent years, other effects besides hypoglycemia have been found, such as a possible therapeutic effect on mental disorders (e.g., anxiety disorder, Alzheimer's disease), cancer, and cardiovascular disease. It also has regulatory effects on intestinal microbiota. The purpose of this review is to summarize the recent investigations of metformin on mental disorders, cardiovascular diseases, cancer, and intestinal microbiota.
